Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$14.70 +3.4%	$13.89	$10.57 ▼ $33.33	$2.14B	1.32	1.13 million shs	1.79 million shs
KNSA Kiniksa Pharmaceuticals	$30.23 +2.4%	$24.27	$17.38 ▼ $30.27	$2.21B	0.06	505,355 shs	1.07 million shs
TYRA Tyra Biosciences	$10.55 +3.7%	$9.31	$6.42 ▼ $29.60	$560.10M	1.07	272,302 shs	194,217 shs
VCEL Vericel	$43.30 -0.2%	$41.26	$37.39 ▼ $63.00	$2.18B	1.33	418,666 shs	239,384 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	+3.38%	+11.53%	+3.11%	-11.92%	-32.72%
KNSA Kiniksa Pharmaceuticals	+2.41%	+10.21%	+12.92%	+40.54%	+53.37%
TYRA Tyra Biosciences	+3.74%	+14.05%	+15.55%	-3.56%	-44.56%
VCEL Vericel	-0.23%	+3.46%	+6.91%	-12.63%	-7.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.2897 of 5 stars	4.5	1.0	4.7	2.3	2.5	0.0
KNSA Kiniksa Pharmaceuticals	2.9697 of 5 stars	3.5	2.0	0.0	3.2	3.3	0.6
TYRA Tyra Biosciences	1.8312 of 5 stars	3.5	0.0	0.0	3.3	2.5	0.0
VCEL Vericel	3.2354 of 5 stars	3.5	3.0	0.0	3.2	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	129.35% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	28.35% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	192.26% Upside
VCEL Vericel	3.00	Buy	$61.14	41.21% Upside

Current Analyst Ratings Breakdown

Latest TYRA, KNSA, VCEL, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/16/2025	KNSA Kiniksa Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00
4/11/2025	VCEL Vericel	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $51.00
4/10/2025	DNLI Denali Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight

(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.46	N/A	N/A	$7.42 per share	1.98
KNSA Kiniksa Pharmaceuticals	$481.17M	4.58	N/A	N/A	$6.23 per share	4.85
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.74 per share	N/A
VCEL Vericel	$238.54M	9.14	$0.01 per share	3,081.95	$4.73 per share	9.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/30/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	120.92	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
TYRA Tyra Biosciences	-$69.13M	-$1.63	N/A	N/A	N/A	N/A	-24.56%	-23.31%	8/6/2025 (Estimated)
VCEL Vericel	-$3.18M	$0.03	721.79	98.41	N/A	1.56%	1.48%	0.96%	7/30/2025 (Estimated)

Latest TYRA, KNSA, VCEL, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/27/2025	Q4 2024	TYRA Tyra Biosciences	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.98	9.98
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
TYRA Tyra Biosciences	N/A	29.55	29.55
VCEL Vericel	N/A	4.61	4.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
KNSA Kiniksa Pharmaceuticals	53.95%
TYRA Tyra Biosciences	84.14%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
KNSA Kiniksa Pharmaceuticals	54.57%
TYRA Tyra Biosciences	15.20%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	42.81 million	Optionable
VCEL Vericel	300	50.34 million	46.79 million	Optionable

TYRA, KNSA, VCEL, and DNLI Headlines

Recent News About These Companies

Congress Asset Management Co. Purchases 22,579 Shares of Vericel Co. (NASDAQ:VCEL)

June 7 at 6:48 AM | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Given Average Recommendation of "Buy" by Analysts

June 7 at 3:31 AM | marketbeat.com

Portside Wealth Group LLC Buys New Position in Vericel Co. (NASDAQ:VCEL)

June 6 at 4:42 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 16,466 Shares of Vericel Co. (NASDAQ:VCEL)

June 3, 2025 | marketbeat.com

Wellington Management Group LLP Buys 701,064 Shares of Vericel Co. (NASDAQ:VCEL)

May 30, 2025 | marketbeat.com

Voloridge Investment Management LLC Acquires Shares of 27,345 Vericel Co. (NASDAQ:VCEL)

May 30, 2025 | marketbeat.com

Vericel's (VCEL) Overweight Rating Reiterated at Stephens

May 24, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AG

May 24, 2025 | marketbeat.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23, 2025 | benzinga.com

Vericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial Markets

May 23, 2025 | marketbeat.com

Rafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)

May 22, 2025 | marketbeat.com

Lazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)

May 21, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Ameriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)

May 19, 2025 | marketbeat.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 17, 2025 | investing.com

Vericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by Brokerages

May 15, 2025 | marketbeat.com

StockNews.com Downgrades Vericel (NASDAQ:VCEL) to Sell

May 15, 2025 | marketbeat.com

Northern Trust Corp Buys 44,397 Shares of Vericel Co. (NASDAQ:VCEL)

May 13, 2025 | marketbeat.com

Leerink Partnrs Has Positive Outlook of Vericel Q4 Earnings

May 13, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Issues Earnings Results

May 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, KNSA, VCEL, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$14.70 +0.48 (+3.38%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$14.52 -0.17 (-1.19%)

As of 06/6/2025 06:45 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$30.23 +0.71 (+2.41%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$28.46 -1.77 (-5.84%)

As of 06/6/2025 07:19 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Tyra Biosciences NASDAQ:TYRA

$10.55 +0.38 (+3.74%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$11.77 +1.22 (+11.56%)

As of 06/6/2025 07:53 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Vericel NASDAQ:VCEL

$43.30 -0.10 (-0.23%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$43.30 0.00 (0.00%)

As of 06/6/2025 05:03 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time